Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-649-8600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$94.39 million
Profitability
Miscellaneous
Employees482
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Agios Pharmaceuticals (NASDAQ:AGIO) Frequently Asked Questions
What is Agios Pharmaceuticals' stock symbol?
Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."
How were Agios Pharmaceuticals' earnings last quarter?
Agios Pharmaceuticals Inc (NASDAQ:AGIO) announced its earnings results on Thursday, August, 1st. The biopharmaceutical company reported ($1.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.70) by $0.17. The biopharmaceutical company had revenue of $26.22 million for the quarter, compared to analysts' expectations of $27.05 million. Agios Pharmaceuticals had a negative net margin of 383.05% and a negative return on equity of 59.89%. The company's revenue for the quarter was down 35.1% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.19) earnings per share. View Agios Pharmaceuticals' Earnings History.
When is Agios Pharmaceuticals' next earnings date?
What price target have analysts set for AGIO?
9 brokers have issued 12 month price objectives for Agios Pharmaceuticals' stock. Their predictions range from $45.00 to $82.00. On average, they anticipate Agios Pharmaceuticals' share price to reach $66.17 in the next twelve months. This suggests a possible upside of 94.6% from the stock's current price. View Analyst Price Targets for Agios Pharmaceuticals.
What is the consensus analysts' recommendation for Agios Pharmaceuticals?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Agios Pharmaceuticals.
Has Agios Pharmaceuticals been receiving favorable news coverage?
Media stories about AGIO stock have trended neutral this week, according to InfoTrie. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Agios Pharmaceuticals earned a daily sentiment score of 0.4 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Agios Pharmaceuticals.
Are investors shorting Agios Pharmaceuticals?
Agios Pharmaceuticals saw a increase in short interest in September. As of September 30th, there was short interest totalling 11,500,000 shares, an increase of 8.5% from the August 30th total of 10,600,000 shares. Based on an average daily volume of 581,400 shares, the days-to-cover ratio is currently 19.8 days. Approximately 19.8% of the company's shares are short sold. View Agios Pharmaceuticals' Current Options Chain.
Who are some of Agios Pharmaceuticals' key competitors?
Some companies that are related to Agios Pharmaceuticals include Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Perrigo (PRGO), SAGE Therapeutics (SAGE), Catalent (CTLT), Jazz Pharmaceuticals (JAZZ), Dr.Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Beigene (BGNE), Amarin (AMRN), Horizon Therapeutics (HZNP), The Medicines (MDCO), Ascendis Pharma A/S (ASND) and Blueprint Medicines (BPMC).
What other stocks do shareholders of Agios Pharmaceuticals own?
Who are Agios Pharmaceuticals' key executives?
Agios Pharmaceuticals' management team includes the folowing people:
- Jacqualyn A. Fouse, Chief Executive Officer & Director
- Andrew J. Hirsch, CFO & Head-Corporate Development
- Scott Biller, Chief Scientific Officer
- Chris Bowden, Chief Medical Officer
- Clive Patience, Senior Vice President-Technical Operations
How do I buy shares of Agios Pharmaceuticals?
Shares of AGIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Agios Pharmaceuticals' stock price today?
One share of AGIO stock can currently be purchased for approximately $34.01.
How big of a company is Agios Pharmaceuticals?
Agios Pharmaceuticals has a market capitalization of $2.00 billion and generates $94.39 million in revenue each year. The biopharmaceutical company earns $-346,020,000.00 in net income (profit) each year or ($6.03) on an earnings per share basis. Agios Pharmaceuticals employs 482 workers across the globe.View Additional Information About Agios Pharmaceuticals.
What is Agios Pharmaceuticals' official website?
How can I contact Agios Pharmaceuticals?
Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-8600 or via email at [email protected]
MarketBeat Community Rating for Agios Pharmaceuticals (NASDAQ AGIO)
MarketBeat's community ratings are surveys of what our community members think about Agios Pharmaceuticals and other stocks. Vote "Outperform" if you believe AGIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
